Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | JAK3 | P52333 | 6/20 | 1.00 |
| ▸ | JAK2 | O60674 | 3/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | BMX | P51813 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 6/20 | 0.80 |
| ▸ | FLT3 | P36888 | 2/20 | 0.80 |
| ▸ | CTSC | P53634 | 2/20 | 0.80 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.80 |
| ▸ | ITK | Q08881 | 1/20 | 0.80 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.80 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.80 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.80 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.80 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.80 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854720 | 1.00 | EGFR (1.00) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL29351880 | 1.00 | EGFR (1.00) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL10127835 | 0.91 | EGFR (0.84) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL1707115 | 0.91 | EGFR (0.83) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL10127821 | 0.90 | EGFR (0.82) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL22210826 | 0.90 | EGFR (0.84) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL19725766 | 0.90 | EGFR (0.84) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL30672758 | 0.90 | EGFR (0.81) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL16372156 | 0.90 | EGFR (0.81) | EGFRJAK3JAK2BLKBMX | |
| SCHEMBL10127920 | 0.89 | EGFR (0.81) | EGFRJAK3JAK2BLKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-3296905-B1 | METHOD FOR IDENTIFYING NEW MARKERS | ALACRIS THERANOSTICS GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | G1 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2020206035-A1 | TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2426213-A1 | Marker for sunitnib resistance formation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885JAK3 37/4885JAK2 14/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | EGFR 2297/4885JAK3 2116/4885JAK2 1775/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | EGFR 1810/4885JAK3 2810/4885JAK2 2669/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | EGFR 2297/4885JAK3 2116/4885JAK2 1775/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | EGFR 2685/4885JAK3 4820/4885JAK2 4713/4885 |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | EGFR, CDK4, CDK6 | EGFR 1/4885JAK3 149/4885JAK2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.